NIH signs on IDT Biologika to manufacture clinical trial supply

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Lucshen)
(Image: Getty/Lucshen)

Related tags: Nih, Biologics, Phase, IND applications

The NIH has contracted IDT Biologika to manufacture five E. coli master cell banks for BLA, IND, and Phase I/II trial supply.

IDT BIologika, a global vaccine and biopharmaceutical contract development and manufacturing organization (CDMO), has been awarded a task order from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to manufacture five E. coli master ell banks.

Germany-based IDT Biologika will manufacture the five master cell banks at its Rockville, Maryland facility, which its CEO Jürgen Betzing said is well-positioned to meet the requirements.

The Maryland facility was opened in 2015​ and is equipped to handle process development, cell banking, current good manufacturing practice (cGMP) manufacturing, purification, and fill and finish services. IDT Biologika Corporation, a subsidiary of IDT Biologika, acquired the site from Aeras​.

This contract is within the 10-year Indefinite Delivery, Indefinite Quantity (IDIQ) agreement with the NIAID. The 2018 agreement supports early research and development projects and provides manufacturing of Phase I/II clinical material for the use in Investigational New Drug (IND) applications and Biologic License Applications (BLA).

Vaccine development grants

The Coalition for Epidemic Preparedness Innovations​ (CEPI) also recently collaborated with IDT Biologika, granting the CRO $36m in 2018 to develop a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

In 2016, IDT Biologika was also contracted by the Biomedical Advanced Research and Development Authority (BARDA) to provide live virus filling and finishing services​ at its Maryland facility.

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us

Products

View more

Webinars